F8基因变异影响血友病A携带者对去氨加压素的反应
本研究分析了361例血友病A携带者(HAC)使用去氨加压素(DDAVP)后FVIII和血管性血友病因子(VWF)的反应,建立群体药代动力学/药效学模型,纳入F8基因变异(无义变异143例[39.6%],非无义变异218例[60.4%])及人口学和实验室协变量。结果显示,无义变异者较非无义变异者DDAVP后FVIII:C反应更差,体重<35 kg者反应也较差。
要点
- DDAVP后峰值FVIII:C≥0.5 IU/mL者占95.6%(345/361),≥0.8 IU/mL者占78.7%(284/361)。
- 无义F8变异者较非无义变异者峰值FVIII:C更低(1.04 vs 1.23 IU/mL),FVIII:C清除率更高(5898.83 vs 2704.06 IU/h)。
- 体重<35 kg的HAC较35-70 kg者峰值FVIII:C更低、清除率更高、AUC0-12h更低、FVIII:C≥0.8 IU/mL时间更短。
核心结论
- 在血友病A携带者中,DDAVP后FVIII反应受F8基因型和体重强烈影响。
研究设计与样本
- 研究分析了361例血友病A携带者DDAVP后FVIII和VWF反应,建立群体药代动力学/药效学模型,纳入F8基因变异(无义变异n=143[39.6%],非无义变异n=218[60.4%])及人口学和实验室协变量。
主要发现
- DDAVP前后平均基础、峰值和恢复期FVIII活性(FVIII:C)分别为0.34 IU/mL(0.08-0.65)、1.13 IU/mL(0.19-2.69)和2.85 IU/mL(1.06-7.13)。
- 峰值FVIII:C≥0.5 IU/mL者占95.6%(345/361),≥0.8 IU/mL者占78.7%(284/361)。
- 无义变异者较非无义变异者平均峰值FVIII:C更低(1.04 vs 1.23 IU/mL;P < 5 × 10-5),FVIII:C正常化患者比例更低(91.6% vs 98.1%;P = .0068)。
- 无义变异者较非无义变异者平均FVIII:C清除率更高(5898.83 vs 2704.06 IU/h;P = 1.58 × 10-15),前12小时平均FVIII:C曲线下面积更低(AUC0-12h =7.73 vs 9.06 IU/mL per hour;P < 5 × 10-6),FVIII:C≥0.8 IU/mL平均时间更短(1.9 vs 4.1小时;P < 6 × 10-6)。
- 体重<35 kg的HAC较体重35-70 kg者峰值FVIII:C更低、FVIII:C清除率更高、AUC0-12h更低、FVIII:C≥0.8 IU/mL时间更短。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Desmopressin (DDAVP) is often administered to correct factor VIII (FVIII) levels in female hemophilia A carriers (HACs). However, the post-DDAVP FVIII pharmacokinetic profiles have been reported only in small series in HACs. Therefore, this study analyzed the post-DDAVP FVIII and von Willebrand factor (VWF) response in 361 HACs. A population pharmacokinetic/pharmacodynamic model was developed to analyze the VWF and FVIII levels by taking into account the F8 gene variants (n = 143 [39.6%] with null; and n = 218 [60.4%] with non-null variants), demographic and laboratory covariates. The before/after DDAVP mean basal, peak and recovery FVIII activity (FVIII:C) levels were 0.34 IU/mL (0.08-0.65), 1.13 IU/mL (0.19-2.69), and 2.85 IU/mL (1.06-7.13), respectively. Peak FVIII:C was ≥0.5 IU/mL in 95.6% (345/361) and ≥0.8 IU/mL in 78.7% (284/361) of patients. The covariate analysis showed a poorer DDAVP FVIII:C response for null than non-null F8 variants: lower mean FVIII:C peak (1.04 vs 1.23 IU/mL; P < 5 × 10-5) and patients percentage with normalized FVIII:C (91.6% vs 98.1%; P = .0068), higher mean FVIII:C clearance (5898.83 vs 2704.06 IU/h; P = 1.58 × 10-15), lower mean FVIII:C area under the curve during the first 12 hours (AUC0-12h =7.73 vs 9.06 IU/mL per hour; P < 5 × 10-6), and shorter mean time with FVIII:C ≥0.8 IU/mL (1.9 vs 4.1 hours; P < 6 × 10-6). HAC with body weight <35 kg had lower peak FVIII:C, higher FVIII:C clearance, lower AUC0-12h, and shorter time with FVIII:C ≥0.8 IU/mL than HAC with body weight 35 to 70 kg. In HACs, the post-DDAVP FVIII response is strongly influenced by the F8 genotype and body weight.
引用
- Guillet B, d'Oiron R, Trossaert M, et al. F8 gene variants influence the response to desmopressin in hemophilia A carriers. Blood. 2025. PMID: 40845131. doi:10.1182/blood.2025029829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。